Everest Medicines Ltd. (6HN)

Overview

Everest Medicines Limited, incorporated in 2017 and headquartered in Shanghai, China, operates as a biopharmaceutical entity primarily focused on the discovery, licensing-in, development, and commercialization of novel therapies and vaccines. The company's mission is to address critical unmet medical needs in Greater China and other Asia Pacific regions. Through its engagement in various stages of drug development and commercialization, Everest Medicines aims to bring innovative medical solutions to patients in areas where treatment options are limited or non-existent.

Products and Services

• Nefecon: An oral formulation of budesonide, designed for the treatment of immunoglobulin A nephropathy (IgAN), a disease that causes damage to the kidneys due to the deposition of the IgA antibody. Nefecon aims to address the underlying inflammation and preserve kidney function.
• Xerava: A fully synthetic fluorocycline intravenous antibiotic for treating infections caused by gram-positive, gram-negative, and anaerobic pathogens. Xerava represents a new option for serious infections, including those resistant to conventional antibiotics.
• Taniborbactam: Currently in phase 3 clinical trials, Taniborbactam is a beta-lactamase inhibitor (BLI) developed for patients with serious bacterial infections. This BLI works by combating resistance to beta-lactam antibiotics — a major concern in managing bacterial infections.
• Etrasimod: An oral selective sphingosine 1-phosphate (S1P) receptor modulator in phase 3 clinical trials for treating moderate-to-severe active ulcerative colitis. Etrasimod aims to reduce inflammation and assist in tissue healing in the colon.
• Zetomipzomib: An immunoproteasome inhibitor in phase 2b clinical trials for various immune-mediated disorders including lupus nephritis. Zetomipzomib targets the immune system's proteasome, potentially reducing the autoimmune response affecting the kidneys.
• EVER001: A covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, currently in phase 1b clinical trials for the treatment of renal diseases. By inhibiting BTK, EVER001 seeks to reduce the progression of renal diseases through a novel mechanism of action.
• mRNA platform therapeutic vaccines: Developed for cancer and autoimmune diseases, these vaccines leverage the modern mRNA platform to stimulate a patient’s immune system to target and fight disease, offering a new avenue for the treatment of these conditions.
• EVER206: A phase 1 clinical trial polymyxin derivative aimed at treating multidrug-resistant gram-negative bacterial infections with a focus on reducing toxicity and nephrotoxicity, thereby providing a safer treatment alternative for severe infections.